Allakos Inc. (NASDAQ:ALLK) Shares Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Allakos Inc. (NASDAQ:ALLK) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 936,797 shares of the company’s stock after acquiring an additional 159,095 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.05% of Allakos worth $1,134,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in ALLK. Deep Track Capital LP increased its holdings in shares of Allakos by 14.1% in the 4th quarter. Deep Track Capital LP now owns 5,704,282 shares of the company’s stock valued at $6,902,000 after purchasing an additional 704,282 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in Allakos by 25.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 209,900 shares of the company’s stock valued at $254,000 after buying an additional 42,500 shares in the last quarter. RA Capital Management L.P. acquired a new stake in shares of Allakos during the 4th quarter valued at approximately $1,367,000. Jane Street Group LLC boosted its stake in shares of Allakos by 92.6% during the 4th quarter. Jane Street Group LLC now owns 101,097 shares of the company’s stock worth $122,000 after acquiring an additional 48,602 shares in the last quarter. Finally, Lynx1 Capital Management LP acquired a new stake in shares of Allakos in the 4th quarter worth approximately $4,390,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ALLK. Citizens Jmp cut Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Piper Sandler downgraded Allakos from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 27th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $2.00.

Allakos Price Performance

Shares of ALLK opened at $0.33 on Wednesday. Allakos Inc. has a 1-year low of $0.22 and a 1-year high of $1.56. The stock has a market cap of $29.76 million, a price-to-earnings ratio of -0.16 and a beta of 0.15. The firm has a 50 day simple moving average of $0.30 and a 200-day simple moving average of $0.66.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.